Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant | Zendy

Sebastian Neggers | Zendy; Maarten O. van Aken | Zendy; Wouter W. de Herder | Zendy; Richard A. Feelders | Zendy; J. A. M. J. L. Janssen | Zendy; Xavier Badı́a | Zendy; Susan M. Webb | Zendy; A. J. van der Lely | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant

Author(s) -

Sebastian Neggers,

Maarten O. van Aken,

Wouter W. de Herder,

Richard A. Feelders,

J. A. M. J. L. Janssen,

Xavier Badı́a,

Susan M. Webb,

A. J. van der Lely

Publication year - 2008

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2008-0669

Subject(s) - pegvisomant , acromegaly , medicine , quality of life (healthcare) , placebo , somatostatin , crossover study , endocrinology , gastroenterology , hormone , growth hormone , alternative medicine , nursing , pathology

The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research